Emmecell Appoints Ramin Valian as Chief Executive Officer to Advance Magnetic Cell Delivery Platform




Emmecell Appoints Ramin Valian as Chief Executive Officer to Advance Magnetic Cell Delivery Platform

MENLO PARK, Calif.–(BUSINESS WIRE)–Emmecell, a clinical-stage biotechnology company pioneering magnetic cell delivery technologies for ophthalmic disease, today announced the appointment of Ramin Valian as Chief Executive Officer. A veteran biopharmaceutical executive, Valian brings more than 20 years of global commercial and strategic leadership in eye care, with expertise spanning corneal disease, surgical and interventional glaucoma, retina, and consumer eye care. He has successfully led the launch of six ophthalmic products across therapeutics and medical technologies.

Valian joins Emmecell following a distinguished career at Allergan and AbbVie, where he played key roles in global strategy, clinical development, and commercialization of high-impact ophthalmic products. His decision to join Emmecell underscores his confidence in the company’s science, platform, and potential to deliver meaningful clinical impact for patients.

“I believe Emmecell’s magnetic cell delivery technology has the potential to fundamentally redefine ophthalmic treatment—from corneal disease to geographic atrophy,” said Ramin Valian, Chief Executive Officer of Emmecell. “The ability to precisely and non-invasively position therapeutic cells opens new possibilities for regenerative medicine. I’m honored to lead Emmecell as it advances toward pivotal clinical development and commercialization.”

Emmecell’s magnetic cell delivery (MCD) platform enables targeted placement of therapeutic cells through a minimally invasive procedure. The company’s lead program is being developed as a potential non-surgical alternative to corneal transplant, addressing limitations in donor tissue availability and surgical burden. Emmecell is also advancing a novel cell therapy for geographic atrophy, a significant unmet need in retinal disease.

“We are pleased to welcome Ramin to Emmecell,” said Jeffrey L. Goldberg, M.D., Ph.D., Co-Founder and Chairman of the Board. “His leadership experience and commitment to patient-centered innovation make him the right CEO for Emmecell as we advance programs in both corneal and retinal disease.”

As CEO, Valian will oversee corporate strategy, clinical and regulatory development, partnerships, and operational growth as the company prepares for pivotal cornea trials and commercialization.

About Emmecell

Emmecell is a clinical-stage biotechnology company developing magnetic cell delivery technologies to treat corneal disease, geographic atrophy, and other ophthalmic conditions. Its platform enables controlled, targeted positioning of therapeutic cells to support minimally invasive, regenerative alternatives to traditional surgical and pharmacologic therapies.

Contacts

Noelia Kunzevitzky, PhD

Chief Operating Officer

Emmecell

info@emmecell.com
650-769-4232

AGC Biologics Celebrates U.S. and EU Approval of Fondazione Telethon’s Waskyra™ Treatment for Wiskott-Aldrich Syndrome




AGC Biologics Celebrates U.S. and EU Approval of Fondazione Telethon’s Waskyra™ Treatment for Wiskott-Aldrich Syndrome

This further establishes the global leadership of AGC Biologics’ Milan Cell and Gene Center of Excellence in number of commercial products approved

MILAN–(BUSINESS WIRE)–#CGT–With the decision by the U.S. Food and Drug Administration and the European Commission to grant market authorization for Waskyra™, a gene therapy to treat Wiskott-Aldrich syndrome, AGC Biologics’ Milan Cell and Gene Center of Excellence announced it will continue to support the commercial development of this vital, life-changing therapy for young patients worldwide.

Wiskott-Aldrich syndrome is a rare immune disorder affecting approximately 1 in 250,000 live male births, leading to severe infections, increased bruising and bleeding, and other complications starting in early childhood due to problems with platelet production. Current treatment options include supportive therapies aimed at managing and preventing clinical manifestations, or a stem cell transplant from a familial donor.

Developed by Fondazione Telethon, a longtime client of AGC Biologics Milan, Waskyra is an ex vivo gene therapy using autologous CD34+ hematopoietic stem and progenitor cells that have been transduced with a lentiviral vector. Waskyra received orphan drug designation in both the EU/US and on November 13, 2025, the Committee for Medicinal Products for Human Use adopted a positive opinion of Waskyra that was sent to the European Commission to decide on EU marketing authorization.

To assist the effort to create a better treatment option for those afflicted by Wiskott-Aldrich syndrome, AGC Biologics developed and produced clinical grade lentiviral vectors carrying the relevant therapeutic gene and manufactured patient-specific genetically engineered cells from preclinical to commercial, assisting with regulatory filings at every step.

This adds to a growing list of cell and gene therapies manufactured by AGC Biologics approved for commercial use, and the third time AGC Biologics partnered with developers to continue manufacturing a rare disease drug considered not economically viable by traditional industry standards due to small population size and high manufacturing price per patient. In 2023, Fondazione Telethon became the first non-profit organization to take on the commercialization of a gene therapy, with AGC Biologics as their chosen manufacturer for lentiviral vectors and genetically engineered cells through the preclinical, clinical, and commercial development of their ultra-rare disease treatment pipeline for the last two decades.

“For nearly 15 years, we’ve worked with Fondazione Telethon to produce the lentiviral vector and the genetically modified cells that enable this therapy as part of our commitment to advancing innovative therapies for patients worldwide,” said Luca Alberici, General Manager, AGC Biologics Milan. “Fondazione Telethon has an ethical responsibility to ensure this life-changing therapy reaches every patient who needs it and AGC is fully committed to deliver on this responsibility.”

“We are extremely proud of the FDA approval and the positive CHMP opinion for Waskyra™—milestones made possible also thanks to the high-quality services provided by AGC Biologics,” said Celeste Scotti, Head of Research and Development at Fondazione Telethon. “Their expertise in producing lentiviral vectors and genetically modified cells has been instrumental in bringing this therapy to patients and in strengthening Fondazione Telethon’s role as a leading player in the field of advanced therapies.”

With its 30-year track record of regulatory approvals by the EMA and FDA, the AGC Biologics Milan site is a global leader with deep expertise in complex cell and gene therapy projects. The team has guided numerous products to commercial stages, manufactured hundreds of batches for clinical supply, and consistently met the highest global regulatory guidelines, quality performance metrics, and the unique complexities of technology transfers and manufacturing scale-up.

About Fondazione Telethon

Fondazione Telethon is an Italian non-profit biomedical organization committed to advancing research on rare and complex genetic diseases. For over 35 years, it has supported high-impact science aimed at developing innovative treatments and improving the lives of people affected by these conditions.

About AGC Biologics

AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. AGC Biologics is a part of AGC Inc.’s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com.

Contacts

AGC Inc. corporate contact: info-pr@agc.com

AGC Biologics media contact: ksills@agcbio.com

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)




Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Company Announcement

• Based on the topline results from the EPCORE^® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps

COPENHAGEN, Denmark–(BUSINESS WIRE)–Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])^* in patients treated with epcoritamab monotherapy. Additionally, improvements were observed in the complete response rate, duration of response, and time to next treatment among patients treated with epcoritamab monotherapy. EPCORE DLBCL-1 is the first Phase 3 study to demonstrate an improvement in PFS in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who were treated with a CD3xCD20 T-cell engaging bispecific monotherapy. The study demonstrated an overall survival (OS) of HR: 0.96 [95% CI 0.77 to 1.20], which did not reach statistical significance.

The global study enrolled 483 patients with R/R DLBCL with at least one prior line of therapy (73% had received two or more prior lines) who were ineligible for high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT). The study evaluated the safety and efficacy of epcoritamab monotherapy compared to investigator’s choice of either rituximab plus gemcitabine and oxaliplatin (R-GemOx), or bendamustine plus rituximab (BR).

The adverse events observed in this study appear consistent with the known safety profile of epcoritamab. Further analysis of the results is ongoing, including the potential impact of various factors, such as the COVID-19 pandemic and increasing availability of novel anti-lymphoma therapies. The full trial results will be submitted for presentation at a future medical meeting. Genmab and AbbVie will engage with global regulatory authorities to discuss next steps.

Data is anticipated in 2026 from two Phase 3 trials evaluating fixed duration epcoritamab in patients with DLBCL, including EPCORE DLBCL-2, a front-line study evaluating epcoritamab in combination with standard-of-care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), and EPCORE DLBCL-4, evaluating epcoritamab in combination with lenalidomide versus chemo-immunotherapy in patients with relapsed or refractory DLBCL.

“The EPCORE DLBCL-1 trial is the first Phase 3 study evaluating a bispecific antibody monotherapy to demonstrate improvements in progression-free survival in patients with relapsed or refractory DLBCL,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “The results from this global trial contribute to the growing body of evidence supporting epcoritamab and build upon the robust foundation established by epcoritamab, which has been used to treat thousands of patients in need of additional therapeutic options. Together with our partner, AbbVie, we remain deeply committed to advancing the development of epcoritamab as a potential core therapy across a broad range of B-cell malignancies.”

Epcoritamab (approved under the brand name EPKINLY^® in countries including the U.S. and Japan, and as TEPKINLY^® in the European Union) has received regulatory approval in certain lymphoma indications in more than 65 countries. Genmab and AbbVie remain committed to advancing the potential of epcoritamab, with ongoing clinical programs evaluating the therapy as a monotherapy and in combination regimens across treatment lines and a broad range of hematologic malignancies.

About Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) worldwide, accounting for approximately 25-30 percent of all NHL cases.^i,ii In the U.S., there are approximately 25,000 new cases of DLBCL diagnosed each year.ⁱⁱⁱ DLBCL can arise in lymph nodes as well as in organs outside of the lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men.^iv,v DLBCL is a fast-growing type of NHL, a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell. For many people living with DLBCL, their cancer either relapses, which means it may return after treatment, or becomes refractory, meaning it does not respond to treatment. Although new therapies have become available, treatment management can remain a challenge.^iv,vi

About the EPCORE DLBCL-1 Trial

EPCORE DLBCL-1 (NCT04628494) is a global Phase 3 open label, multi-center, randomized trial to evaluate the efficacy of epcoritamab (GEN3013, DuoBody^®-CD3xCD20) compared to investigator’s choice of chemotherapy, either rituximab plus gemcitabine plus and oxaliplatin (R-GemOx), or bendamustine plus rituximab (BR), in patients with relapsed or refractory DLBCL who are ineligible for high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT). The trial started on January 13, 2021, and is ongoing.

More information on this trial can be found at https://www.clinicaltrials.gov/.

About Epcoritamab

Epcoritamab is an IgG1-bispecific antibody created using Genmab’s proprietary DuoBody technology and administered subcutaneously. Genmab’s DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.^vii

Epcoritamab (approved under the brand name EPKINLY^® in the U.S. and Japan, and TEPKINLY^® in the EU) has received regulatory approval in certain lymphoma indications in several territories. Where approved, epcoritamab is a readily accessible therapy. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies’ oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the investigational R/R FL indication and additional approvals for the R/R DLBCL indication.

Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes three ongoing Phase 3, open-label, randomized trials, among them a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL (NCT05578976), a trial evaluating epcoritamab in combination with lenalidomide compared to chemotherapy infusion in patients with R/R DLBCL (NCT06508658), and a trial evaluating epcoritamab in combination with lenalidomide and rituximab (R²) compared to chemoimmunotherapy in patients with previously untreated FL (NCT06191744). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit www.clinicaltrials.gov for more information.

EPKINLY^® (epcoritamab-bysp) U.S. INDICATIONS AND IMPORTANT SAFETY INFORMATION

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with:

• certain types of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory), after 2 or more treatments.
  • EPKINLY for the treatment of DLBCL is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY.
• follicular lymphoma (FL) that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab
• follicular lymphoma (FL) that has come back or that did not respond after receiving 2 or more treatments.

It is not known if EPKINLY is safe and effective in children.

Important Warnings—EPKINLY can cause serious side effects, including:

• Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
• Neurologic problems that can be serious, and can be life-threatening, and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

People with DLBCL or high-grade B-cell lymphoma should be hospitalized for 24 hours after receiving their first full dose of EPKINLY on Day 15 of Cycle 1 due to the risk of CRS and neurologic problems.

People with follicular lymphoma (FL) may need to be hospitalized after receiving their first full dose of EPKINLY on Day 22 of Cycle 1 due to the risk of CRS.

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away.

EPKINLY can cause other serious side effects, including:

• Infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, feeling weak or generally unwell, or confusion.
• Low blood cell counts, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia and lymphopenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.

Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

The most common side effects of EPKINLY when used alone in DLBCL or high-grade B-cell lymphoma or FL include CRS, injection site reactions, tiredness, muscle and bone pain, fever, diarrhea, COVID-19, rash, and stomach-area (abdominal) pain. The most common severe abnormal laboratory test results with EPKINLY when used alone include decreased white blood cells, decreased red blood cells, and decreased platelets.

The most common side effects of EPKINLY when used together with lenalidomide and rituximab in FL include rash, upper respiratory tract infections, tiredness, injection site reactions, constipation, diarrhea, CRS, pneumonia, COVID-19, and fever. The most common severe abnormal laboratory test results with EPKINLY when used together with lenalidomide and rituximab include decreased white blood cells and decreased platelets.

These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

Please see Full Prescribing Information and Medication Guide, including Important Warnings.

Globally, prescribing information varies; refer to the individual product label for complete information.

About Genmab

Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^®; HuMax^®; DuoBody^®; HexaBody^®; DuoHexaBody^®, HexElect^® and KYSO™. EPCORE^®, EPKINLY^®, TEPKINLY^® and their designs are trademarks of AbbVie Biotechnology Ltd.

Contacts

Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs

T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: acn@genmab.com

Fluoxetine Hydrochloride (CAS 56296-78-7) Industry Research 2025: Global Market Trends 2019-2024 and Forecasts 2025-2029 – Applications, Manufacturing Method, Patents, Suppliers, Prices, End-users – ResearchAndMarkets.com




Fluoxetine Hydrochloride (CAS 56296-78-7) Industry Research 2025: Global Market Trends 2019-2024 and Forecasts 2025-2029 – Applications, Manufacturing Method, Patents, Suppliers, Prices, End-users – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Fluoxetine Hydrochloride (CAS 56296-78-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering.

This report on Fluoxetine hydrochloride provides comprehensive insights, including general information, synonyms, chemical composition, safety, hazards, handling, storage, and toxicological and ecological details, along with transport information. This in-depth study serves as a vital resource for understanding the Fluoxetine hydrochloride market landscape and its growth potential worldwide.

It explores various applications and examines manufacturing methods, supported by an analysis of relevant patents. The global market analysis covers constraints, drivers, and opportunities from 2019 to 2024, supply and demand dynamics, suppliers and regional overviews across Europe, Asia, North America, and other regions.

The report forecasts future trends and supply-demand scenarios up to 2029, with detailed market predictions by region. Additionally, it analyzes market prices across different regions and evaluates the end-use sectors for Fluoxetine hydrochloride.

The Fluoxetine hydrochloride global market report covers the following key points:

• Fluoxetine hydrochloride description, applications and related patterns
• Fluoxetine hydrochloride market drivers and challenges
• Fluoxetine hydrochloride manufacturers and distributors
• Fluoxetine hydrochloride prices
• Fluoxetine hydrochloride end-users
• Fluoxetine hydrochloride downstream industries trends

Key questions answered in the report:

• What were the main trends of the global Fluoxetine hydrochloride market in 2019-2024?
• What was the size of the global Fluoxetine hydrochloride market in 2019-2024?
• Who are the main players in the global Fluoxetine hydrochloride market?
• Which drivers and challenges will determine the development of the global Fluoxetine hydrochloride market during 2025-2029?
• What will the CAGRs be for the global product industry?

Key Topics Covered:

1. FLUOXETINE HYDROCHLORIDE

1.1. General information, synonyms

1.2. Composition, chemical structure

1.3. Safety information

1.4. Hazards identification

1.5. Handling and storage

1.6. Toxicological & ecological information

1.7. Transport information

2. FLUOXETINE HYDROCHLORIDE APPLICATIONS

3. FLUOXETINE HYDROCHLORIDE MANUFACTURING METHODS

4. FLUOXETINE HYDROCHLORIDE PATENTS

5. FLUOXETINE HYDROCHLORIDE WORLD MARKET ANALYSIS

5.1. Fluoxetine hydrochloride market constraints, drivers and opportunities in 2019-2024

5.2. Fluoxetine hydrochloride supply/demand in 2019-2024

5.3. Fluoxetine hydrochloride market overview by region – Europe, Asia, North America, etc.

6. MANUFACTURERS OF FLUOXETINE HYDROCHLORIDE

6.1. Fluoxetine hydrochloride manufacturers in Europe

6.2. Fluoxetine hydrochloride manufacturers in Asia

6.3. Fluoxetine hydrochloride manufacturers in North America

6.4. Fluoxetine hydrochloride manufacturers in RoW

7. SUPPLIERS OF FLUOXETINE HYDROCHLORIDE

7.1. Fluoxetine hydrochloride suppliers in Europe

7.2. Fluoxetine hydrochloride suppliers in Asia

7.3. Fluoxetine hydrochloride suppliers in North America

7.4. Fluoxetine hydrochloride suppliers in RoW

8. FLUOXETINE HYDROCHLORIDE WORLD MARKET FORECAST

8.1. Future trends in global Fluoxetine hydrochloride market

8.2. Fluoxetine hydrochloride supply/demand forecast to 2029

8.3. Fluoxetine hydrochloride market forecast to 2029 by region (Europe, Asia, North America, etc.)

9. FLUOXETINE HYDROCHLORIDE MARKET PRICES

9.1. Fluoxetine hydrochloride prices in Europe

9.2. Fluoxetine hydrochloride prices in Asia

9.3. Fluoxetine hydrochloride prices in North America

9.4. Fluoxetine hydrochloride prices in RoW

10. FLUOXETINE HYDROCHLORIDE END-USE SECTOR

For more information about this report visit https://www.researchandmarkets.com/r/qp8ifv

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Brotizolam (CAS 57801-81-7) Industry Research 2025: Global Market Trends 2019-2024 and Forecasts 2025-2029 – Applications, Manufacturing Method, Patents, Suppliers, Prices, End-users – ResearchAndMarkets.com




Brotizolam (CAS 57801-81-7) Industry Research 2025: Global Market Trends 2019-2024 and Forecasts 2025-2029 – Applications, Manufacturing Method, Patents, Suppliers, Prices, End-users – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Brotizolam (CAS 57801-81-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering.

This report on Brotizolam provides comprehensive insights, including general information, synonyms, chemical composition, safety, hazards, handling, storage, and toxicological and ecological details, along with transport information. This in-depth study serves as a vital resource for understanding the Brotizolam market landscape and its growth potential worldwide.

It explores various applications and examines manufacturing methods, supported by an analysis of relevant patents. The global market analysis covers constraints, drivers, and opportunities from 2019 to 2024, supply and demand dynamics, suppliers and regional overviews across Europe, Asia, North America, and other regions.

The report forecasts future trends and supply-demand scenarios up to 2029, with detailed market predictions by region. Additionally, it analyzes market prices across different regions and evaluates the end-use sectors for Brotizolam.

The Brotizolam global market report covers the following key points:

• Brotizolam description, applications and related patterns
• Brotizolam market drivers and challenges
• Brotizolam manufacturers and distributors
• Brotizolam prices
• Brotizolam end-users
• Brotizolam downstream industries trends

Key questions answered in the report:

• What were the main trends of the global Brotizolam market in 2019-2024?
• What was the size of the global Brotizolam market in 2019-2024?
• Who are the main players in the global Brotizolam market?
• Which drivers and challenges will determine the development of the global Brotizolam market during 2025-2029?
• What will the CAGRs be for the global product industry?
• And many others

Key Topics Covered:

1. BROTIZOLAM

1.1. General information, synonyms

1.2. Composition, chemical structure

1.3. Safety information

1.4. Hazards identification

1.5. Handling and storage

1.6. Toxicological & ecological information

1.7. Transport information

2. BROTIZOLAM APPLICATIONS

3. BROTIZOLAM MANUFACTURING METHODS

4. BROTIZOLAM PATENTS

5. BROTIZOLAM WORLD MARKET ANALYSIS

5.1. Brotizolam market constraints, drivers and opportunities in 2019-2024

5.2. Brotizolam supply/demand in 2019-2024

5.3. Brotizolam market overview by region – Europe, Asia, North America, etc.

6. MANUFACTURERS OF BROTIZOLAM

6.1. Brotizolam manufacturers in Europe

6.2. Brotizolam manufacturers in Asia

6.3. Brotizolam manufacturers in North America

6.4. Brotizolam manufacturers in RoW

7. SUPPLIERS OF BROTIZOLAM

7.1. Brotizolam suppliers in Europe

7.2. Brotizolam suppliers in Asia

7.3. Brotizolam suppliers in North America

7.4. Brotizolam suppliers in RoW

8. BROTIZOLAM WORLD MARKET FORECAST

8.1. Future trends in global Brotizolam market

8.2. Brotizolam supply/demand forecast to 2029

8.3. Brotizolam market forecast to 2029 by region (Europe, Asia, North America, etc.)

9. BROTIZOLAM MARKET PRICES

9.1. Brotizolam prices in Europe

9.2. Brotizolam prices in Asia

9.3. Brotizolam prices in North America

9.4. Brotizolam prices in RoW

10. BROTIZOLAM END-USE SECTOR

For more information about this report visit https://www.researchandmarkets.com/r/1rwrf8

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference




BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference

Company outlines foundational hematology leadership, multiple 2026 data catalysts, a unique global clinical development superhighway, and continued financial excellence

SAN CARLOS, Calif.–(BUSINESS WIRE)–$ONC #BeOne—BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will outline the pillars of its growing global oncology leadership during its presentation today at the 44^th Annual J.P. Morgan Healthcare Conference in San Francisco.

John V. Oyler, Co-Founder, Chairman, and CEO at BeOne, will highlight the Company’s transformative leadership in treating B-cell malignancies. The presentation will feature BRUKINSA^®, the global leader among Bruton’s tyrosine kinase (BTK) inhibitors, as well as foundational hematology assets: sonrotoclax, a next-generation and potentially best-in-class B-cell lymphoma 2 (BCL2) inhibitor that received its first global regulatory approvals on December 30, and BGB-16673, a potentially first-in-class and best-in-class BTK chimeric degradation activation compound (CDAC). In addition, Mr. Oyler will share further information on BeOne’s global development superhighway, which encompasses global, wholly internal, and competitively advantaged clinical capabilities that can greatly reduce the cost and time to develop a new medicine, thereby increasing the speed of access to innovation for patients around the world.

“BeOne is emerging as the world’s leading oncology company with established leadership in the treatment of B-cell malignancies, an industry-leading pipeline and a unique set of internal capabilities to address tremendous unmet patient need around the world,” Mr. Oyler said. “BRUKINSA has entrenched itself as the best-in-class, foundational BTK inhibitor and global revenue leader with an unparallelled long-term efficacy and safety profile across all approved indications. The investigational combination of BRUKINSA and BCL2 inhibitor sonrotoclax has the potential to change the fixed-duration treatment landscape for CLL with best-in-class rates and kinetics of minimal residual disease. BGB-16673 is the most advanced BTK degrader in the clinic and continues to emerge as a potential first-in-class and best-in-class treatment. Combining one of the industry’s most innovative research teams with our vertically integrated clinical development capabilities puts us in a strong position for our next phase of growth with a solid financial profile and a growing global footprint.”

Key themes from BeOne’s presentation (7:30 a.m. PT, Tuesday, Jan. 13, 2026) at the J.P. Morgan Healthcare Conference include:

BeOne is the only company with potentially best-in-class, foundational medicines in three key MOAs in CLL

BeOne is the leading company in the treatment of chronic lymphocytic leukemia (CLL) with three approved or clinical-stage foundational medicines addressing all patient subtypes.

BRUKINSA is now the global revenue leader in the BTKi class and the only BTKi to demonstrate superior progression-free survival (PFS) and cardiac safety profile versus ibrutinib in a Phase 3 head-to-head trial. At the American Society of Hematology (ASH) Annual Meeting in December, the Company presented landmark six-year results from the global, Phase 3 SEQUOIA trial of BRUKINSA versus bendustamine plus rituximab (BR) in treatment-naïve CLL or small lymphocytic lymphoma with an estimated 74% PFS compared with 32% PFS for BR. The overall survival (OS) at 72 months was 84% for BRUKINSA and 80% with BR. After adjusting for COVID-19, the OS rates were 88% and 82%, respectively.

BeOne is rapidly advancing the investigational combination of BRUKINSA and sonrotoclax as a potential best-in-class fixed-duration regimen for the treatment of first-line CLL with clinical results showing potential best-in-class rates of undetectable minimal residual disease (uMRD) at the earliest time as exploratory endpoints. The Company anticipates uMRD results from the Phase 3 CELESTIAL trial of zanubrutinib plus sonrotoclax (ZS) versus venetoclax plus obinutuzumab (VO) in 2026.

In addition, the Company continues to advance BGB-16673 as a potentially first-in-class and best-in-class targeted degrader of BTK with Phase 1 trial results in heavily pretreated CLL patients at a median follow-up of 18 months demonstrating an overall response rate of 86% and 12-month progression-free survival of 79%. The Company anticipates potentially pivotal Phase 2 trial results for BGB-16673 in R/R CLL in 2026.

BeOne’s peerless global development superhighway combined with an industry-leading oncology R&D team drives faster development, accelerated regulatory registrations, and broader global patient access

BeOne is leveraging one of the largest oncology research teams in the industry alongside nearly 6,000 clinical development and manufacturing colleagues supporting the Company’s wholly internal, strategically advantaged global development superhighway to rapidly bring our medicines to cancer patients around the world.

The Company’s dedicated team of research scientists holds deep expertise in designing innovative small-molecule inhibitors, biologics, targeted protein degraders, multispecific antibodies and antibody drug conjugates. In the past 18 months, the Company has advanced 15 New Molecular Entities (NME) into the clinic across a broad range of modalities and expects to deliver an additional eight to 10 NMEs per year into the clinic starting in 2026. BeOne plans to share updates for the following programs, each of which has achieved clinical proof of concept and presents a significant market opportunity: CDK4 inhibitor, B7-H4 ADC, PRMT5 inhibitor, GPC3x41BB bispecific antibody, and CEA ADC.

A strong financial profile enables investment for BeOne’s future growth

BeOne’s strong financial position enables the Company to achieve greater global scale while maintaining profitability in 2026 and beyond.

The Company generated more than $350 million in free cash flow in the third quarter of 2025 with more than $4 billion in cash on hand. BeOne will continue to invest in driving innovation across its hematology and solid tumor pipelines to maximize long-term value for patients and shareholders while pursuing value-creating business development, including opportunities to leverage the Company’s global development superhighway.

Live webcast of BeOne’s presentation can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. Archived replays will be available on the Company’s website.

About BeOne Medicines

BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team of nearly 12,000 colleagues spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.

To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne’s anticipated presentation at the 44^th Annual J.P. Morgan Healthcare Conference; the potential of sonrotoclax to be a best-in-class BCL2 inhibitor and BGB-16673 to be a first-in-class BTK CDAC; BeOne’s internal capabilities to drive innovation to address unmet patient need around the world; the potential of the combination of BRUKINSA and sonrotoclax to treat CLL; BeOne’s positioning for growth; anticipated timing of results from BeOne’s clinical trials of ZS versus VO and BGB-16673; BeOne’s expectations with respect to advancing NMEs into the clinic; BeOne’s ability to achieve greater global scale while maintaining profitability; BeOne’s plans to continue to invest in commercial assets and geographies that drive profitable growth; and BeOne’s plans, commitments, aspirations and goals under the caption “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. BeOne’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties.

Contacts

Investor Contact
Liza Heapes

+1 857-302-5663

ir@beonemed.com

Media Contact
Kyle Blankenship

+1 667-351-5176

media@beonemed.com

Vizient and AdventHealth Expand Agreement for Advanced Data and Digital Services




Vizient and AdventHealth Expand Agreement for Advanced Data and Digital Services

IRVING, Texas–(BUSINESS WIRE)–Vizient^®, the nation’s largest provider-driven healthcare performance improvement company, today announced a renewed and expanded agreement with AdventHealth, one of the largest non-profit health systems in the United States. The expanded collaboration enhances AdventHealth’s access to Vizient’s robust data and digital offerings, including the Vizient Clinical Data Base and the AAMC-Vizient Clinical Practice Solutions Center^®.

“This expanded collaboration underscores AdventHealth’s approach to using data and digital innovation to deliver more connected, personal and effective whole-person care,” said Michael Cacciatore MD, chief clinical officer for AdventHealth. “By harnessing Vizient’s advanced analytics, we can translate complex data into meaningful insights that help our teams deliver the safest, highest-quality care and help people feel whole.”

In 2024, Vizient recognized five AdventHealth hospitals with a Bernard A. Birnbaum, MD, Quality Leadership Award, which recognizes participating healthcare organizations on the quality of patient care in safety, mortality, effectiveness, efficiency, patient centeredness and variation in care. The award factors in measures from the Vizient Clinical Data Base and includes performance data from the HCAHPS survey and the CDC’s National Healthcare Safety Networks.

Through the agreement, AdventHealth will expand access to the Clinical Data Base to more than 50 facilities for comparative benchmarking, performance analytics and clinical insights to support data-informed strategies in quality improvement and value-based care initiatives. The inclusion of the AAMC-Vizient Clinical Practice Solutions Center^® offers physician-level analytics to support academic and community practice excellence.

“We are honored to expand our collaboration with AdventHealth, a system known for its forward-thinking approach to clinical innovation,” said Arun Ramasubramanian, president, Data and Digital, Vizient. “Our Data and Digital solutions will continue to empower AdventHealth in their mission to deliver high-quality, efficient and personalized care.”

The expanded agreement builds upon a decades-long partnership and reflects the evolving needs of health systems to integrate AI, analytics and operational tools in pursuit of higher-value care.

Learn more about Vizient data and digital solutions.

About Vizient, Inc.

Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company, provides solutions and services to more than two-thirds of the nation’s acute care providers and more than one-third of ambulatory providers. Vizient offers proprietary data and analytics to deliver unique clinical and operational insights and a contract portfolio representing $156 billion in annual purchasing volume enabling the delivery of cost-effective care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.

Contacts

Media Contact

Nancy Matocha

(972) 830-9756

nancy.matocha@vizientinc.com

Oscar Health, Inc. 2025 Fourth Quarter and Full Year Earnings Conference Call




Oscar Health, Inc. 2025 Fourth Quarter and Full Year Earnings Conference Call

NEW YORK–(BUSINESS WIRE)–Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR), a leading healthcare technology company, will release its fourth quarter and full year 2025 financial results before the market opens on Tuesday, February 10, 2026.

Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows:

Live Call: 1.855.761.5600

Conference ID: 7768132

Webcast

The call will be archived and available on Oscar’s investor relations website (ir.hioscar.com) following February 10, 2026 for a period of 90 days.

About Oscar Health

Oscar Health, Inc. (“Oscar”) is a leading healthcare technology company built around a full stack technology platform and a relentless focus on serving our members. Oscar has been challenging the status quo in the healthcare system since its founding in 2012, and is dedicated to making a healthier life accessible and affordable for all. Oscar offers Individual & Family plans and health technology solutions that power the healthcare industry through +Oscar. Oscar’s technology drives superior experiences, deep engagement, and high-value clinical care, earning us the trust of approximately 2.1 million members, as of September 30, 2025.

Contacts

Investor Contact:

Chris Potochar

VP of Investor Relations

ir@hioscar.com

Media Contact:

Kristen Prestano

VP of Communications

press@hioscar.com

Astoriom Appoints Will Edwards as Chief Executive Officer




Astoriom Appoints Will Edwards as Chief Executive Officer

Strategic appointment to support global scale-up of sample management operations

ROCHDALE, United Kingdom–(BUSINESS WIRE)–#Astoriom–Astoriom, a global quality expert in safeguarding scientific research and consumer product sample assets, today announced the appointment of Will Edwards, as Chief Executive Officer. Will will continue to build on Astoriom’s strong foundations to support the next phase of growth across its international portfolio of sample stability storage, biorepository services, validation solutions, as well as sample storage design and disaster recovery. His appointment reflects Astoriom’s continued focus on operational excellence, resilience and scaling high-quality, compliant sample management solutions for organizations operating in complex, regulated life science and consumer product environments. He succeeds Lori A. Ball, who has decided to transition into a board seat.

Will brings extensive international leadership experience in the storage, logistics and technology sectors, most recently as CEO of Spectrum Storage Group. With a customer-focused, data-driven approach honed at global companies, including Google and Bain & Co, he has led businesses through periods of rapid growth and operational transformation over the last two decades. Will holds an MBA from INSEAD and an MS from Stanford University.

Will’s appointment comes at a pivotal moment for Astoriom, as demand continues to grow for outsourced, resilient, and compliant sample management and storage solutions to protect high-value research and product samples across pharmaceutical, biotechnology, medical device, and consumer product sectors worldwide. His experience leading complex storage operations and scaling service-led platforms will support Astoriom’s ambition to continue to expand internationally, working with global life science organizations, while maintaining the highest standards of quality, compliance, and customer trust.

Will Edwards, CEO of Astoriom, said: “Astoriom has built a strong reputation as a global industry leader for quality, reliability, and technical excellence in a sector where trust and resilience are essential. The business has grown significantly in the last couple of years and is at an exciting stage of development. The team is committed to providing accessible stability storage and biorepository solutions to safeguard the integrity and viability of valuable sample assets; I look forward to working with them to continue to scale capabilities worldwide, while remaining firmly focused on compliance, operational excellence, and long-term customer partnerships.”

For more information about Astoriom and its leadership team, please visit: https://www.astoriom.com/about/

Please contact Codon Communications for high-resolution images.

Contacts

Codon Communications
Dr Michelle Ricketts

Tel: +447789053885

Email: michelle.ricketts@codoncommunications.com

Nuclera Extends Series C Funding to $87M to Advance Antibody Engineering




Nuclera Extends Series C Funding to $87M to Advance Antibody Engineering

• Additional $12M financing led by Elevage Medical Technologies and Jonathan Milner alongside existing investors British Business Bank, and GK Goh
• The funding will accelerate development of eProtein Discovery for full-format antibody expression, purification, and binding validation

CAMBRIDGE, England and BOSTON–(BUSINESS WIRE)–Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, today announced a USD $12 million financing extension, bringing the Company’s total Series C funding to USD $87 million. The raise was led by Elevage Medical Technologies and Jonathan Milner, joined by existing investors British Business Bank and GK Goh. The investment will accelerate the integration of antibody expression and binding validation capabilities into the Company’s eProtein Discovery benchtop system, which enables multiplex protein screening, characterization, and expression in-house.

Expanding eProtein Discovery with antibody-specific capabilities represents a strategic step as Nuclera moves into AI-enabled protein engineering, addressing a critical industry need for scalable, standardized, and high-quality datasets that can be used to power next-generation AI models in biologics discovery. The advancement will enable researchers to perform end-to-end expression, purification, and binding validation of full-format antibodies on an integrated, high-throughput system.

Since the closure of its previous Series C financing¹ in 2024, the Company has advanced its eProtein Discovery capabilities with the addition of a membrane protein workflow², extended its global footprint to broaden customer access across APAC and the Middle East^3,4,5, and initiated a collaboration with Cytiva to accelerate the path from DNA to fully purified and characterized proteins to better understand drug-target interactions⁶. In parallel, the eProtein Discovery system was installed at Domainex⁷, the first CRO implementation of the system, streamlining protein production services and further validating the system’s commercial and scientific impact.

Dr Michael Chen, CEO and co-founder, Nuclera, said: “This financing underscores our growing momentum and demonstrates that we are expanding eProtein Discovery into one of the fastest-growing segments of biologics R&D. Scientists increasingly require scalable, high-quality datasets to power AI models in biologics discovery. We are positioning Nuclera to become a foundational platform for the future of protein and antibody engineering, ultimately accelerating therapeutic discovery timelines.”

Dr Michael Wasserman, Chief Operating Officer, Elevage Medical Technologies, commented: “Since our initial investment, Nuclera has made meaningful progress in expanding the capabilities, adoption, and global reach of the eProtein Discovery platform. The extension of the system into full-format antibody expression, purification, and binding validation represents a significant step forward, particularly as biologics discovery becomes increasingly driven by AI-enabled workflows that require scalable, high-quality datasets. Elevage is proud to continue supporting Nuclera as it evolves into a foundational platform for protein and antibody engineering, helping researchers accelerate discovery timelines and reduce friction across the drug development process.”

Dr Jonathan Milner, Chairman of the Nuclera Board of Directors, founder and former CEO of Abcam, Inc and CEO of Meltwind Advisory, added: “Nuclera is solving one of the most pressing bottlenecks in biologics discovery – the slow, fragmented, and resource-intensive process of synthesising full-format antibodies. The team’s success in membrane proteins, one of the most challenging protein classes, combined with their microfluidic expertise, places them in a unique position to transform antibody development workflows.”

Combining unique cell-free expression systems, novel digital microfluidics, and robust screening data, eProtein Discovery provides clear guidance on which protein has the best chance of success early on, thereby reducing the time, cost, and uncertainty traditionally associated with protein expression and purification.

Taylor Wessing LLP acted as legal advisor to Nuclera on the financing.

1. Nuclera closes $75 million USD financing
2. Nuclera Expands eProtein Discovery™ with New Membrane Protein Workflow
3. Nuclera Expands Global Footprint with New Distribution Partnerships Across APAC and the Middle East
4. Nuclera expands access to eProtein Discovery for APAC customers with distributor agreement in Australia and New Zealand
5. Nuclera eProtein Discovery System installed at leading Universities in Taiwan – Nuclera
6. Nuclera and Cytiva Join Forces to Accelerate Drug Discovery
7. Nuclera’s eProtein Discovery system installed at Domainex to streamline protein production services

For more information about Nuclera’s eProtein Discovery system, please visit: https://www.nuclera.com/system/

Contacts

Dr Ben Rutter

Zyme Communications

+44(0)7920 770 935

ben.rutter@zymecommunications.com